Provided by Tiger Fintech (Singapore) Pte. Ltd.

HENLIUS

40.350
+1.4003.59%
Volume:926.69K
Turnover:36.34M
Market Cap:21.93B
PE:24.93
High:40.400
Open:38.950
Low:37.800
Close:38.950
Loading ...

BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius

Reuters
·
29 Apr

BRIEF-Shanghai Henlius Biotech Enters License Agreement With Sandoz For Hlx13

Reuters
·
29 Apr

Shanghai Henlius Biotech Inc - Sandoz to Pay Henlius $31 Million Upfront

THOMSON REUTERS
·
29 Apr

Shanghai Henlius Biotech Inc - Application for International Multi-Center- Phase 3 Clinical Trial of Hlx22, Others, Approved in Germany

THOMSON REUTERS
·
28 Apr

Henlius Biotech Licenses Lung Cancer Drug Hansizhuang for Commercialization in South Korea

MT Newswires Live
·
25 Apr

BRIEF-Shanghai Henlius Biotech Enters License Agreement With Alvogen Korea

Reuters
·
25 Apr

Shanghai Henlius Biotech - Enters License Agreement With Alvogen Korea

THOMSON REUTERS
·
25 Apr

Fosun International Unit to Boost Stake in Henlius Biotech

MT Newswires Live
·
22 Apr

Henlius Doses First Patient in Breast Cancer Drug Study

MT Newswires Live
·
21 Apr

BRIEF-Shanghai Fosun Pharmaceutical's Unit To Buy Stake In Henlius Biotech

Reuters
·
21 Apr

Shanghai Fosun Pharmaceutical Says Unit Plans to Buy Around 3.87% Stake in Henlius Biotech for HK$ 517.4 Mln

THOMSON REUTERS
·
21 Apr

Phase 3 Study for Henlius, Essex's Wet Age-Related Macular Degeneration Drug Reaches Primary Endpoint; Essex Shares Up 11%

MT Newswires Live
·
03 Apr

BRIEF-Shanghai Henlius Biotech Updates On Phase 3 Clinical Study Of HLX04-O

Reuters
·
02 Apr

Shanghai Henlius Biotech - Recombinant Anti-Vegf Humanised Monoclonal Antibody Injection Hlx04-O Phase 3 Clinical Study Met Primary Study Endpoint

THOMSON REUTERS
·
02 Apr

Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug

MT Newswires Live
·
28 Mar

BRIEF-Shanghai Henlius Biotech Updates On Pertuzumab Biosimilar HLX11

Reuters
·
28 Mar

Shanghai Henlius Biotech Inc - Marketing Authorization Application ( for Pertuzumab Biosimilar Hlx11 Validated by European Medicines Agency

THOMSON REUTERS
·
28 Mar

Shanghai Henlius Biotech Gets Approval for Kidney Treatment Clinical Trial in China; Shares Rise 3%

MT Newswires Live
·
26 Mar

BRIEF-Shanghai Henlius Biotech Updates On Phase 2 Clinical Trial Of HLX79 Injection

Reuters
·
25 Mar

Shanghai Henlius Biotech - Application for Phase 2 Clinical Trial of Hlx79 Injection in Combination With Hanlikang Approved by Nmpa

THOMSON REUTERS
·
25 Mar